: Bharat Biotech completes enrollment of 25,800 volunteers for Covaxin Phase-3 trials #IndiaNEWS #Coronavirus Hyderabad: Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3

@IndiaNEWS

Posted in: #Coronavirus #IndiaNEWS

Bharat Biotech completes enrollment of 25,800 volunteers for Covaxin Phase-3 trials #IndiaNEWS #Coronavirus
Hyderabad: Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 trials of its COVID-19 vaccine Covaxin. This information was given by Suchitra Ella, joint MD of Bharat Biotech International Ltd here Thursday. In a message posted on the company’s Twitter account, Ella thanked clinical trial sites, principal investigators and health workers for their support and trust in the ‘public- private partnership’ vaccine discovery.
“My deep appreciation to all the volunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of Indias 1st fully indigenous COVID-19 vaccine,??? Ella said referring to Covaxin.
The Drug Controller General of India (DCGI) has recently given emergency use authorisation for Covaxin.
The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India. The company had said it is the only Phase-3 efficacy study for a COVID-19 vaccine, and the largest efficacy trial (Phase-3) ever conducted for any vaccine in India.
 

Stock Market NEWS Best intraday tips Intraday Stocks below 100

Share & Forward! Do Not Share

0 Reactions   React

Replies (0) Report

Login to post a comment!